This study aims to evaluate the efficacy and safety of co-administration of DWC202206 and DWC202207 in patients with concomitant hypertension and hyperlipidemia.
The study design is a randomized, double-blind, multicenter clinical trial. The patients were randomly assigned to each group. Primary endpoint was the change of MSSBP based on baseline between Treatment arm and control 1 arm and the change of LDL-C based on baseline between arm and control 2 arm.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
214
Drug of DWC202206 A mg
Drug of DWC202207 B/C mg
Placebo of DWC202206 A mg
Kangbuk Samsung Hospital
Seoul, South Korea
The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm
Time frame: 8 weeks
The change of LDL-C based on baseline between treatment arm and control 2 arm
Time frame: 8 weeks
The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm
Time frame: 4 weeks
The change of LDL-C based on baseline between treatment arm and control 2 arm
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo of DWC202207 B/C mg